Paul Tudor Jones Intra Cellular Therapies, Inc. Transaction History

Tudor Investment Corp Et Al

$19.2 Billion
Q2 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 51,901 shares of ITCI stock, worth $3.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

51,901

Holding current value

$3.8 Million

% of portfolio

0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$64.76 - $79.84 $3.36 Million - $4.14 Million	51,901 New	51,901 $3.55 Million
Q4 2023 Feb 14, 2024	BUY	$46.37 - $73.65 $708,348 - $1.13 Million	15,276 Added 42.11%	51,555 $3.69 Million
Q3 2023 Nov 15, 2023	SELL	$52.09 - $64.1 $296,756 - $365,177	-5,697 Reduced 13.57%	36,279 $1.89 Million
Q2 2023 Aug 14, 2023	BUY	$54.67 - $66.44 $2.29 Million - $2.79 Million	41,976 New	41,976 $2.66 Million
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $1.34 Million - $1.89 Million	31,431 Added 167.84%	50,158 $2.33 Million
Q2 2022 Aug 15, 2022	BUY	$43.0 - $65.64 $805,261 - $1.23 Million	18,727 New	18,727 $1.07 Million
Q4 2021 Feb 14, 2022	SELL	$35.2 - $53.42 $657,465 - $997,778	-18,678 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$28.72 - $42.49 $536,432 - $793,628	18,678 New	18,678 $696,000
Q1 2018 May 15, 2018	SELL	$15.16 - $25.49 $484,589 - $814,787	-31,965 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$14.27 - $16.79 $399,931 - $470,556	-28,026 Reduced 46.72%	31,965 $463,000
Q3 2017 Nov 14, 2017	BUY	$10.77 - $22.1 $646,103 - $1.33 Million	59,991	59,991 $947,000

Others Institutions Holding ITCI

# of Institutions

400

Shares Held

87.2M

Call Options Held

309K

Put Options Held

302K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $6.92B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account